DESERT MOUNTAIN ENERGY CORP (DME.CA) Fundamental Analysis & Valuation

TSX-V:DME • CA25043D1078

Current stock price

0.435 CAD
-0.02 (-3.33%)
Last:

This DME.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DME.CA Profitability Analysis

1.1 Basic Checks

  • In the past year DME has reported negative net income.
  • In the past year DME has reported a negative cash flow from operations.
  • DME had negative earnings in each of the past 5 years.
  • DME had a negative operating cash flow in each of the past 5 years.
DME.CA Yearly Net Income VS EBIT VS OCF VS FCFDME.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -3.64%, DME is in the better half of the industry, outperforming 74.81% of the companies in the same industry.
  • With a decent Return On Equity value of -3.87%, DME is doing good in the industry, outperforming 76.69% of the companies in the same industry.
Industry RankSector Rank
ROA -3.64%
ROE -3.87%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DME.CA Yearly ROA, ROE, ROICDME.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • DME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DME.CA Yearly Profit, Operating, Gross MarginsDME.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DME.CA Health Analysis

2.1 Basic Checks

  • DME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DME.CA Yearly Shares OutstandingDME.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DME.CA Yearly Total Debt VS Total AssetsDME.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • DME has an Altman-Z score of 6.85. This indicates that DME is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.85, DME is in line with its industry, outperforming 59.40% of the companies in the same industry.
  • There is no outstanding debt for DME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.85
ROIC/WACCN/A
WACC12.04%
DME.CA Yearly LT Debt VS Equity VS FCFDME.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • DME has a Current Ratio of 1.79. This is a normal value and indicates that DME is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.79, DME is in line with its industry, outperforming 48.62% of the companies in the same industry.
  • A Quick Ratio of 1.79 indicates that DME should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.79, DME perfoms like the industry average, outperforming 50.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.79
DME.CA Yearly Current Assets VS Current LiabilitesDME.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DME.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.98% over the past year.
  • Looking at the last year, DME shows a very negative growth in Revenue. The Revenue has decreased by -56.15% in the last year.
  • Measured over the past years, DME shows a decrease in Revenue. The Revenue has been decreasing by -5.28% on average per year.
EPS 1Y (TTM)50.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)-56.15%
Revenue growth 3Y-5.28%
Revenue growth 5YN/A
Sales Q2Q%-53.31%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y350%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year209.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DME.CA Yearly Revenue VS EstimatesDME.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
DME.CA Yearly EPS VS EstimatesDME.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 0.02 -0.02 0.04 -0.04 -0.06

More info and screens

Find the best growth stocksShow best growing peers

3

4. DME.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DME. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 8.45, which indicates a very decent valuation of DME.
  • DME's Price/Forward Earnings ratio is rather cheap when compared to the industry. DME is cheaper than 93.86% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of DME to the average of the S&P500 Index (23.10), we can say DME is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.45
DME.CA Price Earnings VS Forward Price EarningsDME.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DME.CA Per share dataDME.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • DME's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DME.CA Dividend Analysis

5.1 Amount

  • No dividends for DME!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DME.CA Fundamentals: All Metrics, Ratios and Statistics

DESERT MOUNTAIN ENERGY CORP

TSX-V:DME (4/7/2026, 7:00:00 PM)

0.435

-0.02 (-3.33%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-26
Earnings (Next)05-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.63%
Ins Owner ChangeN/A
Market Cap41.77M
Revenue(TTM)306.40K
Net Income(TTM)-1.81M
Analysts84.44
Price Target0.51 (17.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.45
P/S 136.34
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)0.05
Fwd EY11.84%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.64%
ROE -3.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 263.31%
Cap/Sales 133.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.79
Altman-Z 6.85
F-Score4
WACC12.04%
ROIC/WACCN/A
Cap/Depr(3y)2257.95%
Cap/Depr(5y)19865.9%
Cap/Sales(3y)624.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y350%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-56.15%
Revenue growth 3Y-5.28%
Revenue growth 5YN/A
Sales Q2Q%-53.31%
Revenue Next Year209.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year340.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.31%
OCF growth 3YN/A
OCF growth 5YN/A

DESERT MOUNTAIN ENERGY CORP / DME.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DESERT MOUNTAIN ENERGY CORP?

ChartMill assigns a fundamental rating of 2 / 10 to DME.CA.


What is the valuation status for DME stock?

ChartMill assigns a valuation rating of 3 / 10 to DESERT MOUNTAIN ENERGY CORP (DME.CA). This can be considered as Overvalued.


How profitable is DESERT MOUNTAIN ENERGY CORP (DME.CA) stock?

DESERT MOUNTAIN ENERGY CORP (DME.CA) has a profitability rating of 1 / 10.


What is the expected EPS growth for DESERT MOUNTAIN ENERGY CORP (DME.CA) stock?

The Earnings per Share (EPS) of DESERT MOUNTAIN ENERGY CORP (DME.CA) is expected to grow by 350% in the next year.